Kezar Life Sciences develops selective immunoproteasome inhibitors to modulate immune responses in autoimmune disorders, such as lupus nephritis and autoimmune hepatitis. Their approach targets protein homeostasis to halt the secretion of disease-promoting proteins, offering a therapeutic alternative to direct immunosuppression.
Funding
$12.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MVFounders
Product
Problem
Many autoimmune disorders, such as lupus nephritis and autoimmune hepatitis, are currently treated with broad immunosuppressants, which can lead to significant side effects and increased risk of infection. These treatments often fail to selectively target the specific immune pathways driving the disease, resulting in limited efficacy and potential harm to the patient.
Solution
Kezar Life Sciences is developing selective immunoproteasome inhibitors designed to modulate immune responses in autoimmune diseases. Their therapeutic approach focuses on inhibiting protein secretion, specifically targeting the proteins that promote disease progression in both autoimmune disorders and certain cancers. By selectively modulating the immunoproteasome, Kezar aims to halt the production and secretion of these disease-promoting proteins, offering a more targeted and potentially safer alternative to traditional immunosuppression. This approach seeks to rebalance the immune system, reducing inflammation and tissue damage without broadly suppressing immune function.
Target Audience
The primary target audience includes patients suffering from autoimmune disorders like lupus nephritis and autoimmune hepatitis, as well as those with specific types of cancer where protein secretion plays a critical role in disease progression.
Features
- Selective inhibition of the immunoproteasome to modulate immune responses
- Targeted protein secretion inhibition to halt the production of disease-promoting proteins
- Focus on autoimmune disorders, including lupus nephritis and autoimmune hepatitis
- Potential application in oncology by targeting protein secretion necessary for tumor proliferation